A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

NCT00269906 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1265

Enrollment

INDUSTRY

Sponsor class

Conditions

Angina, Unstable
Angioplasty, Transluminal, Percutaneous Coronary

Interventions

DRUG: Abciximab
DRUG: Placebo

Sponsor

Centocor, Inc.